Skip to main content

Table 1 Detailed information of the included head and neck cancer patients

From: Automatic interactive optimization for volumetric modulated arc therapy planning

Patient number Disease site Stage PTV E (cm 3 ) PTV T (cm 3 ) PTV B (cm 3 ) Comp sal * (cm 3 ) Comp swal (cm 3 ) Oral cavity (cm 3 )
1 Larynx T2N2c 428.7 93.7 243.3 66.7 7.1 -
2 Oropharynx T2N2b 441.7 48.3 188.6 82.3 16.5 -
3 Oropharynx T2N2a 240.6 43.4 94.5 42.4 25.0 -
4 Oropharynx T4N1 288.2 57.3 237.5 60.6 10.6 -
5 Oropharynx T4aN1 280.8 79.5 164.5 78.9 32.0 36.7
6 Oropharynx T4aN2b 288.2 57.3 237.5 60.6 10.6 14.6
7 Oropharynx T4aN1 360.4 62.9 143.7 73.0 35.0 57.1
8 Oropharynx T3N1 500.3 87.9 231.7 55.0 11.9 29.4
9 Oropharynx T4aN2c 258.4 155.7 328.9 38.3 4.8 38.1
10 Hypopharynx T2N3 264.0 137.0 607.0 70.8 10.3 60.6
  1. The disease site, stage and volumes of the elective, transition and boost planning target volumes (PTVE, PTVT, PTVB respectively) and the volumes of the composite salivary and swallowing structures for all patients. The oral cavity was included as an organ-at-risk in 6/10 patients.
  2. Abbreviations:
  3. *Compsal = Composite salivary glands. Depending on degree of overlap with the PTVs and choice for inclusion by the treating clinician, compsal could consist of some, or all, of the ipsilateral and contralateral parotid and submandibular glands.
  4. Compswal = Composite swallowing muscles. Could consistent of some, or all, of the upper esophageal sphincter, upper and lower parts of the larynx, the superior, medial and inferior pharyngeal constrictor muscle, the cricopharyngeal muscle and the esophagus.